Logo

Sirna and Lilly Collaborate to Find RNAi-Based Cancer Therapeutics

Jan 27, 2004

NEW YORK, Jan. 27 (GenomeWeb News) - Sirna Therapeutics and Eli Lilly plan to develop RNAi therapeutics for cancer, the companies said today.

 

During the eighteen-month collaboration, the companies will test Sirna's small interfering RNAs against oncology targets from Lilly.

 

According to Sirna, based in Boulder, Colo., this is its first collaboration with a large pharmaceutical company.

 

 

Breaking News
The Scan

Panel Recommends Pfizer-BioNTech Vaccine for Kids

CNN reports that the US Food and Drug Administration advisory panel has voted in favor of authorizing the Pfizer-BioNTech SARS-CoV-2 vaccine for children between 5 and 11 years old.

Sharing How to Make It

Merck had granted a royalty-free license for its COVID-19 treatment to the Medicines Patent Pool, according to the New York Times.

Bring it Back In

Bloomberg reports that a genetic analysis has tied a cluster of melioidosis cases in the US to a now-recalled aromatherapy spray.

Nucleic Acids Research Papers on SomaMutDB, VThunter, SCovid Databases

In Nucleic Acids Research this week: database of somatic mutations in normal tissue, viral receptor-related expression signatures, and more.